B2M and cancer: Using paired tissue samples from patients who received immune checkpoint inhibitors, an increase in the presence of γδ T cells in B2M-deficient cancers was observed, suggesting that γδ T cells play a role in the response to immune checkpoint blockade in patients with dMMR colon cancers; this could be exploited in future therapeutic strategies [69].